462 related articles for article (PubMed ID: 33870531)
1. Baricitinib: From Rheumatoid Arthritis to COVID-19.
Assadiasl S; Fatahi Y; Mosharmovahed B; Mohebbi B; Nicknam MH
J Clin Pharmacol; 2021 Oct; 61(10):1274-1285. PubMed ID: 33870531
[TBL] [Abstract][Full Text] [Related]
2. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib set to join the Covid-19 therapeutic arsenal?
Gudu T; Stober C; Cope AP; Cheriyan J; Galloway J; Wilkinson IB; Kostapanos M; Jayne D; Hall F
Rheumatology (Oxford); 2021 Apr; 60(4):1585-1587. PubMed ID: 33502499
[No Abstract] [Full Text] [Related]
5. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
6. The safety of baricitinib in patients with rheumatoid arthritis.
Honda S; Harigai M
Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
[No Abstract] [Full Text] [Related]
7. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Mogul A; Corsi K; McAuliffe L
Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
[No Abstract] [Full Text] [Related]
10. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
Mendes JT; Balogh EA; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2020 Jun; 21(9):1027-1033. PubMed ID: 32208940
[TBL] [Abstract][Full Text] [Related]
13. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib.
Anjara P; Jiang M; Mundae M
Clin Rheumatol; 2020 Feb; 39(2):613-614. PubMed ID: 31782014
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Hoang TN; Pino M; Boddapati AK; Viox EG; Starke CE; Upadhyay AA; Gumber S; Nekorchuk M; Busman-Sahay K; Strongin Z; Harper JL; Tharp GK; Pellegrini KL; Kirejczyk S; Zandi K; Tao S; Horton TR; Beagle EN; Mahar EA; Lee MYH; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Delmas OM; Wang S; Cooney KA; Sayegh MN; Wang L; Filev PD; Weiskopf D; Silvestri G; Waggoner J; Piantadosi A; Kasturi SP; Al-Shakhshir H; Ribeiro SP; Sekaly RP; Levit RD; Estes JD; Vanderford TH; Schinazi RF; Bosinger SE; Paiardini M
Cell; 2021 Jan; 184(2):460-475.e21. PubMed ID: 33278358
[TBL] [Abstract][Full Text] [Related]
17. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
19. The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks.
Kim SK; Jung UH; Kim JW; Choe JY
Medicine (Baltimore); 2021 Jul; 100(30):e26739. PubMed ID: 34397713
[TBL] [Abstract][Full Text] [Related]
20. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]